Skip to main content
Premium Trial:

Request an Annual Quote

Cenix Expands AstraZeneca Agreement

NEW YORK (GenomeWeb News) – Cenix Bioscience said today that it has expanded an oncology drug research agreement with AstraZeneca to include RNAi-based studies for respiratory and inflammation-related conditions.

Under the new agreement, which expands upon a deal announced in March, Cenix will complete at least three projects using its RNAi gene silencing technology as well as image analysis using Definiens’ Cellenger platform.

These studies will involve multi-pass genome-scale screens using assays developed by AstraZeneca in high-throughput RNAi studies in 384-well and 1,536-well formats.

Financial terms of the expanded agreement were not released.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.